The purpose of this clinical study is to evaluate the efficacy and safety of intramyocardial injection of human induced pluripotent stem cell-derived cardiomyocyte injection (HiCM-188) in patients with advanced heart failure (NYHA Class III-IV)
Aged 18 to 75 years, regardless of gender;
Patients with ischemic heart failure with NYHA functional class III or IV after receiving the maximum tolerated dose of guideline-directed medical therapy (GDMT);
LVEF ≤ 35% as measured by cardiac MRI;
Coronary angiography meeting the indications for coronary artery bypass grafting (CABG) surgery;
Acute viral myocarditis;
Acute phase of myocardial infarction (≤ 3 months);
Cardiac amyloidosis;
Pericarditis;